MicroRNA-29a induces resistance to gemcitabine through the Wnt/β-catenin signaling pathway in pancreatic cancer cells

International Journal of Oncology

Volumn 43, Issue 4, 2013, Pages 1066-1072

  Nagano, Hiroaki ^a   Tomimaru, Yoshito ^a   Eguchi, Hidetoshi ^a   Hama, Naoki ^a   Wada, Hiroshi ^a   Kawamoto, Koichi ^a   Kobayashi, Shogo ^a   Mori, Masaki ^a   Doki, Yuichiro ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Gemcitabine; MicroRNA; MiR 29a; Pancreatic cancer; Wnt catenin signaling pathway

Indexed keywords

BETA CATENIN; DICKKOPF 1 PROTEIN; GEMCITABINE; LIPOCORTIN 5; MICRORNA 29A; SECRETED FRIZZLED RELATED PROTEIN 2; WNT PROTEIN; WNT3A PROTEIN;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL; WESTERN BLOTTING;

APOPTOSIS; BETA CATENIN; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION; WNT SIGNALING PATHWAY;

EID: 84882335174     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2037     Document Type: Article

References (33)

1. Warshaw AL and Fernandez-del Castillo C: Pancreatic carcinoma. N Engl J Med 326: 455-465, 1992.
2. Li D, Xie K, Wolff R and Abbruzzese JL: Pancreatic cancer. Lancet 363: 1049-1057, 2004.
3. Neoptolemos JP, Stocken DD, Friess H, et al: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350: 1200-1210, 2004.
4. Sener SF, Fremgen A, Menck HR and Winchester DP: Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 189: 1-7, 1999.
5. Burris HA III, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997.
6. Oettle H, Post S, Neuhaus P, et al: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297: 267-277, 2007.
7. Akita H, Zheng Z, Takeda Y, et al: Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma. Oncogene 28: 2903-2909, 2009.
8. Nakahira S, Nakamori S, Tsujie M, et al: Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int J Cancer 120: 1355-1363, 2007.
9. Calin GA and Croce CM: MicroRNA-cancer connection: the beginning of a new tale. Cancer Res 66: 7390-7394, 2006.
10. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism and function. Cell 116: 281-297, 2004.
11. Croce CM and Calin GA: miRNAs, cancer and stem cell division. Cell 122: 6-7, 2005.
12. Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866, 2006.
13. Kapinas K, Kessler C, Ricks T, Gronowicz G and Delany AM: miR-29 modulates Wnt signaling in human osteoblasts through a positive feedback loop. J Biol Chem 285: 25221-25231, 2010.
14. Schmittgen TD, Jiang J, Liu Q and Yang L: A high-throughput method to monitor the expression of microRNA precursors. Nucleic Acids Res 32: e43, 2004.
15. Tomimaru Y, Eguchi H, Nagano H, et al: MicroRNA-21 induces resistance to the anti-tumor effect of interferon-/5-fluorouracil in hepatocellular carcinoma cells. Br J Cancer 103: 1617-1626, 2010.
16. Noda T, Nagano H, Takemasa I, et al: Activation of Wnt/beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma. Br J Cancer 100: 1647-1658, 2009.
17. Eguchi H, Nagano H, Yamamoto H, et al: Augmentation of antitumor activity of 5-fluorouracil by interferon alpha is associated with up-regulation of p27Kip1 in human hepatocellular carcinoma cells. Clin Cancer Res 6: 2881-2890, 2000.
18. Jamieson CH, Ailles LE, Dylla SJ, et al: Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 351: 657-667, 2004.
19. Klaus A and Birchmeier W: Wnt signalling and its impact on development and cancer. Nat Rev Cancer 8: 387-398, 2008.
20. Pasca di Magliano M, Biankin AV, Heiser PW, et al: Common activation of canonical Wnt signaling in pancreatic adenocarcinoma. PLoS One 2: e1155, 2007.
21. Zeng G, Germinaro M, Micsenyi A, et al: Aberrant Wnt/beta-catenin signaling in pancreatic adenocarcinoma. Neoplasia 8: 279-289, 2006.
22. Barker N and Clevers H: Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov 5: 997-1014, 2006.
23. Yang W, Yan HX, Chen L, et al: Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. Cancer Res 68: 4287-4295, 2008.
24. Su HY, Lai HC, Lin YW, et al: Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway. Int J Cancer 127: 555-567, 2010.
25. Flahaut M, Meier R, Coulon A, et al: The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/beta-catenin pathway. Oncogene 28: 2245-2256, 2009.
26. Giovannetti E, Funel N, Peters GJ, et al: MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res 70: 4528-4538, 2010.
27. Ali S, Ahmad A, Banerjee S, et al: Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res 70: 3606-3617, 2010.
28. Xiong Y, Fang JH, Yun JP, et al: Effects of microRNA-29 on apoptosis, tumorigenicity and prognosis of hepatocellular carcinoma. Hepatology 51: 836-845, 2010.
29. Fabbri M, Ivan M, Cimmino A, Negrini M and Calin GA: Regulatory mechanisms of microRNAs involvement in cancer. Expert Opin Biol Ther 7: 1009-1019, 2007.
30. Gebeshuber CA, Zatloukal K and Martinez J: miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. EMBO Rep 10: 400-405, 2009.
31. Han YC, Park CY, Bhagat G, et al: microRNA-29a induces aberrant self-renewal capacity in hematopoietic progenitors, biased myeloid development and acute myeloid leukemia. J Exp Med 207: 475-489, 2010.
32. Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM and Cohn DE: The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol 112: 55-59, 2009.
33. Huang Z, Huang D, Ni S, Peng Z, Sheng W and Du X: Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 127: 118-126, 2010.